Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2011 1
2012 1
2013 1
2014 3
2015 1
2020 4
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean nabhan c[au] (177 results)?
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. Cross DA, et al. Among authors: nebhan ca. Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3. Cancer Discov. 2014. PMID: 24893891 Free PMC article.
MEK inhibitors in non-V600 BRAF mutations and fusions.
Johnson DB, Nebhan CA, Noel MS. Johnson DB, et al. Among authors: nebhan ca. Oncotarget. 2020 Nov 3;11(44):3900-3903. doi: 10.18632/oncotarget.27788. eCollection 2020 Nov 3. Oncotarget. 2020. PMID: 33216832 Free PMC article.
Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt RL, Chen SC, Murray E, Johnson CA, Crandall H, O'Neal JF, Al-Rohil RN, Nebhan CA, Bharti V, Dahlman KB, Ayers GD, Yan C, Kelley MC, Kauffmann RM, Hooks M, Grau A, Johnson DB, Vilgelm AE, Richmond A. Shattuck-Brandt RL, et al. Among authors: nebhan ca. Clin Cancer Res. 2020 Jul 15;26(14):3803-3818. doi: 10.1158/1078-0432.CCR-19-1895. Epub 2020 Mar 31. Clin Cancer Res. 2020. PMID: 32234759 Free PMC article.
Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy.
Williams CB, Nebhan CA, Yang J, Starnes LS, Yan C, Vilgelm AE, Chen SC, Dan Ayers G, Abramson V, Mayer IA, Richmond A. Williams CB, et al. Among authors: nebhan ca. Breast Cancer Res Treat. 2020 Nov;184(2):357-364. doi: 10.1007/s10549-020-05846-5. Epub 2020 Aug 7. Breast Cancer Res Treat. 2020. PMID: 32767201
Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.
Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, Lovly CM, Cross DA, Pao W. Meador CB, et al. Among authors: nebhan ca. Mol Cancer Ther. 2015 Feb;14(2):542-52. doi: 10.1158/1535-7163.MCT-14-0723. Epub 2014 Dec 4. Mol Cancer Ther. 2015. PMID: 25477325 Free PMC article.
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.
Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K. Pirazzoli V, et al. Among authors: nebhan c. Cell Rep. 2014 May 22;7(4):999-1008. doi: 10.1016/j.celrep.2014.04.014. Epub 2014 May 9. Cell Rep. 2014. PMID: 24813888 Free PMC article.
15 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page